RT Journal Article
SR Electronic
T1 Investigating resting state neurophysiological markers of apathy and processing speed in prodromal and early-stage manifest Huntington’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.09.22278610
DO 10.1101/2022.08.09.22278610
A1 Marie-Claire Davis
A1 Aron T. Hill
A1 Paul B. Fitzgerald
A1 Neil W. Bailey
A1 Julie C. Stout
A1 Kate E. Hoy
YR 2022
UL http://medrxiv.org/content/early/2022/08/10/2022.08.09.22278610.abstract
AB Sensitive biological markers of non-motor symptoms in Huntington’s disease (HD) are essential for the development and assessment of novel treatments. To this end we used resting state EEG to examine differences in oscillatory activity (analysing the isolated periodic as well as the complete EEG signal) and functional connectivity in 22 people with HD and 20 neurotypical controls. We then assessed the correlations between these neurophysiological markers and clinical measures of apathy and cognitive functioning. Significantly lower theta and greater delta resting state power was seen in the HD group, as well as significantly greater delta connectivity. There was a significant positive correlation between theta power and processing speed, however there were no associations between the neurophysiological and apathy measures. We speculate that these changes in oscillatory power and connectivity reflect ongoing, frontally concentrated degenerative and compensatory processes associated with HD. Our findings support the potential utility of quantitative EEG as a proximate marker for non- motor symptoms in HD.Competing Interest StatementKEH is a founder of Resonance Therapeutics. PBF has received equipment for research from MagVenture A/S, Nexstim, Neuronetics and Brainsway Ltd and funding for research from Neuronetics. PBF is a founder of TMS Clinics Australia and Resonance Therapeutics. JCS is founder and a director of Zindametrix which provides cognitive assessment services in HD clinical trials, and Stout Neuropsych, which provides consultancy services for pharmaceutical companies. MCD, ATH, and NWB have no biomedical financial interests or potential conflicts of interest to report.Clinical TrialAustralian New Zealand Clinical Trials Registry (ANZCTR): 12619000870156Funding StatementMCD was supported by the Research Training Program Stipend and a Monash Graduate Excellence Scholarship. KEH was supported by National Health and Medical Research Council (NHMRC) Fellowships (1082894 and 1135558). PBF was supported by an Investigator Fellowship from the NHMRC (1193596). ATH was supported by an Alfred Deakin Postdoctoral Research Fellowship. We gratefully acknowledge the time, involvement, and feedback from the participants. This research would not have been possible without them. We also acknowledge the assistance with participant recruitment provided by the Statewide Progressive Neurological Disease Service at Calvary Health Care Bethlehem.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Alfred Health Ethics Committee gave ethical approval for this work. Calvary Health Care Bethlehem Research Ethics and Ethics Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors from genuine researchers, provided they agree to preserve the confidentiality of the information.